Vectors in development seek to benefit from earlier trials
The gene therapy field resembles a toolbox containing instruments researchers haven't quite mastered, and the number of devices--viral and nonviral vectors--in this toolbox keeps increasing. "There are all these different tools out there," notes A. Dusty Miller, researcher at Fred Hutchinson Cancer Research Center in Seattle. "People are still trying to figure out what tools to use for what diseases."

Photo: Richard Lobell Photography

BIOBYPASS: During a normal open-heart surgery, a surgeon injects an adenovirus carrying a molecule promoting endothelial cell growth into parts of the heart where a normal bypass can't be effective. Insulin syringes (inset) contain the vectors.
Miller and other gene therapy investigators will report on the strengths and weaknesses of a host of vectors at the American Society of Gene Therapy's inaugural meeting in Seattle May 27-31. James M. Wilson, director of the Institute for...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?